CLINICAL FACTORS ASSOCIATED WITH THE RISK OF PULMONARY SARCOIDOSIS RELAPSE

Area of Science:

• Pulmonology
• Internal Medicine
• Clinical Research

Background:

• Long-term glucocorticosteroid (GCS) therapy for pulmonary sarcoidosis is associated with a high rate of disease relapses.
• Identifying factors predicting relapse is crucial for effective patient management and improving outcomes.

Purpose of the Study:

• To investigate clinical factors associated with relapse in patients with newly diagnosed pulmonary sarcoidosis.
• To develop a clinical phenotype model for patients experiencing relapsing pulmonary sarcoidosis.

Main Methods:

• A cohort of 108 newly diagnosed pulmonary sarcoidosis patients (stages II-III) received GCS therapy (methylprednisolone) with dose tapering.
• Patients were monitored for 2 years post-therapy discontinuation using high-resolution computed tomography (CT).
• Clinical factors were analyzed to identify associations with sarcoidosis relapse using statistical tests (Student's t-test, chi-squared, Fisher's exact test).

Main Results:

• Sarcoidosis relapse occurred in 56 out of 108 patients within the 2-year follow-up period.
• Factors significantly correlated with a higher relapse rate included GCS therapy use, slow symptom development, extrapulmonary lesions, bronchoconstriction, and concomitant diseases.
• A clinical phenotype model for relapsing pulmonary sarcoidosis was established.

Conclusions:

• Glucocorticosteroid therapy is a confirmed risk factor for pulmonary sarcoidosis relapses.
• Clinical factors such as slow symptom onset, extrapulmonary involvement, bronchoconstriction, and comorbidities predict relapse.
• Further research incorporating radiological, immunological, and biochemical factors is needed to refine relapse risk prediction models.